<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Shuman, Jill</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Kay, Jonathan</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Infliximab Biosimilar Appears Safe and Effective Compared with Infliximab for RA</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2014-12-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">11-11</style></pages><abstract><style  face="normal" font="default" size="100%">Because Tumor necrosis factor inhibitors (TNFis) are expensive, however, there is currently much interest in lower-cost biosimilars—biological products that are highly similar to a licensed reference biological product with no clinically meaningful differences in safety, potency, and purity. This article presents results of a phase 3, randomized, double-blind, active comparator trial of the biosimilar BOW015 to its reference drug infliximab in patients with active rheumatoid arthritis.</style></abstract><number><style face="normal" font="default" size="100%">51</style></number><volume><style face="normal" font="default" size="100%">14</style></volume></record></records></xml>